Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have earned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $45.8333.

ZLAB has been the subject of a number of analyst reports. Citigroup reduced their price objective on Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Wall Street Zen lowered Zai Lab from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. JPMorgan Chase & Co. reduced their price target on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. Weiss Ratings lowered shares of Zai Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 4th. Finally, Cantor Fitzgerald dropped their price objective on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a report on Friday, February 27th.

Zai Lab Stock Performance

Shares of NASDAQ ZLAB opened at $17.07 on Monday. Zai Lab has a 1 year low of $15.96 and a 1 year high of $42.00. The stock’s 50-day simple moving average is $20.00 and its 200-day simple moving average is $19.07. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -10.54 and a beta of 0.79.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Wednesday, April 1st. The company reported ($0.50) earnings per share for the quarter. The business had revenue of $99.61 million for the quarter. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. As a group, research analysts predict that Zai Lab will post -2.23 EPS for the current year.

Insider Buying and Selling

In other news, insider Joshua L. Smiley sold 3,017 shares of Zai Lab stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $20.45, for a total transaction of $61,697.65. Following the sale, the insider owned 117,602 shares of the company’s stock, valued at approximately $2,404,960.90. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Richard Gaynor acquired 1,731 shares of Zai Lab stock in a transaction dated Tuesday, March 17th. The shares were acquired at an average price of $18.91 per share, with a total value of $32,733.21. Following the completion of the transaction, the director owned 56,630 shares of the company’s stock, valued at approximately $1,070,873.30. This trade represents a 3.15% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 89,561 shares of company stock valued at $1,811,705 in the last ninety days. Insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zai Lab stock. SG Americas Securities LLC grew its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,396 shares of the company’s stock after purchasing an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. Institutional investors own 41.65% of the company’s stock.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.